Quote | Century Therapeutics Inc. (NASDAQ:IPSC)
Last: | $2.27 |
---|---|
Change Percent: | -0.45% |
Open: | $2.22 |
Close: | $2.27 |
High: | $2.32 |
Low: | $2.18 |
Volume: | 68,720 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Century Therapeutics Inc. (NASDAQ:IPSC)
2024-06-20 11:07:05 ET Summary Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma m...
2024-06-18 16:58:28 ET More on Century Therapeutics Seeking Alpha’s Quant Rating on Century Therapeutics Historical earnings data for Century Therapeutics Financial information for Century Therapeutics Read the full article on Seeking Alpha For...
Message Board Posts | Century Therapeutics Inc. (NASDAQ:IPSC)
Subject | By | Source | When |
---|---|---|---|
CSO sold off his shares not sure why | amateurtrader | investorshub | 03/23/2023 4:24:46 PM |
Extensive epigenetic and transcriptomic donor-specific differences observed in | jondoeuk | investorshub | 03/15/2023 1:46:34 AM |
Link to the webcast https://century-therapeutics-virtual-research-development-da | jondoeuk | investorshub | 11/06/2022 3:00:30 AM |
The company will host a virtual Research and | jondoeuk | investorshub | 11/02/2022 9:58:45 PM |
SITC titles | jondoeuk | investorshub | 10/07/2022 12:42:05 AM |
News, Short Squeeze, Breakout and More Instantly...
Century Therapeutics Inc. Company Name:
IPSC Stock Symbol:
NASDAQ Market:
Century Therapeutics Inc. Website:
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA m...
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD30...
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoim...